Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas
- 1 March 2003
- Vol. 111 (3) , 439-443
- https://doi.org/10.1034/j.1600-0463.2003.t01-1-1110209.x
Abstract
Vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis and may be produced by some cancer cells. Several recent reports have documented that increased expression of VEGF is associated with risk of recurrence or decreased recurrence‐free survival in papillary thyroid cancers (PTC). The aims of this study were to determine whether immunohistochemical expression of VEGF is related to local and distant recurrence of PTC and to evaluate the relationship between hypervascularization and VEGF expression in papillary thyroid carcinomas. VEGF expression was examined immunohistochemically in 48 papillary carcinomas. Ten normal thyroids were used as controls. Patients were followed for 61.7 (range 24–143) months. Twelve of the patients had local and distant recurrences. VEGF immunostaining, blinded for clinicopathological data, was evaluated semiquantitatively by two pathologists. The difference between the recurrent (n:12) and nonrecurrent (n:36) carcinomas was statistically significant (p:0.001). VEGF expression was also stronger in papillary thyroid carcinomas than in normal thyroid tissues. The mean microvascular densities were significantly higher than in normal thyroid tissues. These data indicate that VEGF staining is strongly associated with increased frequency of local and distant recurrence in PTC and that the immunohistochemical profile of the expression may be used as a marker for predicting which tumors have metastatic potential.Keywords
This publication has 13 references indexed in Scilit:
- Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancerSurgery, 2001
- Clinical Relevance of Vascular Endothelial Growth Factor for Thyroid NeoplasmsWorld Journal of Surgery, 2001
- Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular densityHuman Pathology, 2001
- Expression of Angiogenesis Stimulators and Inhibitors in Human Thyroid Tumors and Correlation with Clinical Pathological FeaturesThe American Journal of Pathology, 1999
- Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinomaJournal of Endocrinology, 1999
- Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasisBritish Journal of Cancer, 1999
- Vascular Endothelial Growth Factor Expression Is Higher in Differentiated Thyroid Cancer than in Normal or Benign ThyroidJournal of Clinical Endocrinology & Metabolism, 1997
- Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinomaCancer, 1996
- Clinical Applications of Research on AngiogenesisNew England Journal of Medicine, 1995
- Role of Vegf-Flt Receptor System in Normal and Tumor AngiogenesisPublished by Elsevier ,1995